Navigation Links
ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
Date:4/23/2009

th pegylated interferon and ribavirin. The actual timing for the initiation of Phase II studies may depend on a number of factors, including FDA review timelines, the timing of any potential transaction around ANA598 or ANA773, available cash resources and funding activities, and the engagement of clinical sites.

14 Day Healthy Volunteer Study

Anadys recently completed dosing healthy volunteers in a 14-day study conducted to extend the safety and pharmacokinetic profile of ANA598. Thirty subjects participated in the study, with eight subjects receiving ANA598 and two subjects receiving placebo at each dose level (400 mg once-daily, 800 mg once-daily and 600 mg bid). Subjects received ANA598 or placebo on day one followed by pharmacokinetic assessment over days two and three and received subsequent doses consecutively on days four through fourteen. Preliminary results from the study indicate that ANA598 was generally well-tolerated in all cohorts with no serious adverse events, although three subjects receiving ANA598 (two in the 800 mg once-daily cohort and one in the 600 mg bid cohort) developed grade 2 rash and discontinued treatment after either six or seven days of consecutive dosing. There were no other instances of rash in this or any other study of ANA598. Data receipt and analysis from this study is continuing, and the Company expects to present the results at a clinical conference later this year. The Company believes the results of this study, combined with the results of the Phase Ib study in HCV patients, contribute to the attractive profile of ANA598 as an antiviral likely to be active in long-term studies in combination with pegylated interferon and ribavirin, and help position the program to be ready for Phase II in mid-2009.

Long-term Toxicology Studies

In September 2008, Anadys initiated long-term, chronic toxicology studies of ANA598, of 26 weeks duration in rats a
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
2. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
3. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
9. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
10. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
11. Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Aug. 27, 2015  BioElectronics Corporation (OTC Pink: BIEL), the ... three abstracts featuring the use of ActiPatch®, its novel ... th Congress of the European Pain Federation EFIC®, ... September 2015. The Company will also be exhibiting at ... Gianluca Bagnato , department clinical and experimental rheumatology from ...
(Date:8/27/2015)... Aug. 27, 2015   Americord Registry , a ... and placenta tissue banking company, announced today ... e-commerce website. This new website makes the expecting parent,s ... interactive shopping cart and checkout process. Logo ... blood banking websites make this service difficult to purchase ...
(Date:8/27/2015)... 27, 2015  Zimmer Biomet Holdings, Inc. (NYSE and ... that it will be participating in the Goldman Sachs ... Sachs offices in London on ... Founded in 1927 and headquartered in Warsaw, ... in musculoskeletal healthcare.  We design, manufacture and market orthopaedic ...
Breaking Medicine Technology:BioElectronics Selected to Present its Pain Research and Devices at the European Pain Federation Conference 2Cord Blood Bank Revolutionizes Process of Online Cord Blood Banking 2
... Symmetry Medical Inc. (NYSE: SMA ), a leading ... and other medical markets, announced today that it has entered ... November 3, 2010.  The credit facility includes an "accordion feature" ... million. The credit facility has a term of five years. ...
... Nov. 3, 2010 Aethlon Medical, Inc. (OTC ... in developing therapeutic filtration devices to address infectious ... present tomorrow at the at the Singular Research ... Los Angeles. (Photo:   http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b ) ...
Cached Medicine Technology:Symmetry Medical Closes $200 Million Credit Facility 2Symmetry Medical Closes $200 Million Credit Facility 3Aethlon Medical to Present at the Singular Research Fifth Annual 'Best of the Uncovereds Conference' 2Aethlon Medical to Present at the Singular Research Fifth Annual 'Best of the Uncovereds Conference' 3Aethlon Medical to Present at the Singular Research Fifth Annual 'Best of the Uncovereds Conference' 4
(Date:8/27/2015)... ... ... About 10 percent of mothers experienced chronic, persistent depressive ... than 1,800 people, displacing hundreds of thousands and causing widespread damage estimated at ... most people don’t develop persistent depression after a major disaster like that, a ...
(Date:8/27/2015)... ... ... The Naderi Center is proud to announce that its own Dr. Jessica ... fat. The first and only Food and Drug Administration (FDA) approved treatment for ... only Board Certified surgeon in the D.C., Maryland, Virginia area to offer this innovative, ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... its Krames Patient Education content is ICD-10 ready and available to all clients. ... new ICD-10 code sets, which are more targeted and return a more comprehensive ...
(Date:8/27/2015)... ... 2015 , ... Zensah®, the premium athletic compression company, is ... in the Women’s Tennis Association (WTA). Glushko competes in tennis tournaments around the ... a focus on technology and comfort, Zensah® has developed compression gear to help ...
(Date:8/27/2015)... ... ... In addition to its existing Doctor of Philosophy in Leadership and Doctor ... main campus in Reading: Doctor of Nursing Practice. , Alvernia’s Doctor of Nursing ... for the highest level of clinical nursing practice. , “Our vision is to ...
Breaking Medicine News(10 mins):Health News:About 10 Percent of Mothers Experienced Depression Two Years After Hurricane Katrina, New Study Shows 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 3Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 2Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2
... under the Revised National TB Control Programme (RNTCP) aims ... treatment and diagnostic services to all tuberculosis patients. It ... HIV-positive people are more prone to contracting tuberculosis. Hence ... plan to tackle this issue and multi-drug resistant cases. ...
... and minds of various people world over. But now it ... detox products are to be investigated by the British government. ... attention to some of their medical claims. , ,The ... based on investigations by Real Story's Doctors on a Detox ...
... attempting of suicide is high among the children of men ... the University of British Columbia and several other institutions in ... working or had worked at sawmills in British Columbia - ... ,They collected data on the men's history of employment, their ...
... for calming the nervous, can act otherwise leading ... ,Substances like diphenhydramine, which can be ... says Ursula Sellerberg, spokeswoman for the Federal Organization ... ,Diazepam, the main ingredient in valium, can ...
... new studies, researchers claim that more people could be ... cow disease than previously thought after new evidence emerged ... developing. // According to the scientists from Edinburgh a ... to pass through blood transfusions and surgical instruments, can ...
... market in Norwich is a non-referral drop-in-center aimed at people, ... after its fallen apart. // Founded in 1994, the centre ... mental health charity Rethink. The centre will be launching an ... and shallowness, that follows mental illness. ,The place is ...
Cached Medicine News:Health News:India to Implement National Action Plan against TB-HIV 2Health News:Mad Cow Disease – Worst Is Yet To com 2Health News:Bridging People’s lives, Post Upheava 2
... is suspected, every minute counts. ... allows rapid determination of the ... a single whole blood sample. ... within minutes - saving you ...
... Endoscopic cases it is extremely popular to combine ... Light. This combination affords the surgeon optimal ... an uncomfortable pose. The Dual Light System ... System. As such the light can be ...
... offers all the performance of a major surgical ... use in Outpatient Settings, Minor Procedure Rooms, C-Section, ... single lights either side of the OR table ... General OR when combining Flat Screen LCD Monitors ...
A Western Blot Immunassay for the detection of antibodies to primarily anti-myelin associated glycoproteins (anti-MAG) and other glycolipid autoantibodies in human serum....
Medicine Products: